Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4 by Markees, Thomas G. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
1998-06-17 
Long-term survival of skin allografts induced by donor 
splenocytes and anti-CD154 antibody in thymectomized mice 
requires CD4(+) T cells, interferon-gamma, and CTLA4 
Thomas G. Markees 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Immunology and Infectious Disease Commons 
Repository Citation 
Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, Rossini AA. (1998). Long-
term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized 
mice requires CD4(+) T cells, interferon-gamma, and CTLA4. Open Access Articles. https://doi.org/
10.1172/JCI2703. Retrieved from https://escholarship.umassmed.edu/oapubs/1000 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 2446
 
Markees et al.
 
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/98/06/2446/10 $2.00
Volume 101, Number 11, June 1998, 2446–2455
http://www.jci.org
 
Long-Term Survival of Skin Allografts Induced by Donor Splenocytes and
Anti-CD154 Antibody in Thymectomized Mice Requires CD4
 
1
 
 T Cells, Interferon-
 
g
 
, 
and CTLA4
 
Thomas G. Markees,* Nancy E. Phillips,* Ethel J. Gordon,* Randolph J. Noelle,
 
‡
 
 Leonard D. Shultz,
 
§
 
 John P. Mordes,*
Dale L. Greiner,* and Aldo A. Rossini*
 
*
 
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605; 
 
‡
 
Department of Microbiology, 
Dartmouth Medical School, Lebanon, New Hampshire 03765; and 
 
§
 
The Jackson Laboratory, Bar Harbor, Maine 04609
 
Abstract
 
Treatment of C57BL/6 mice with one transfusion of BALB/c
spleen cells and anti-CD154 (anti–CD40-ligand) antibody
permits BALB/c islet grafts to survive indefinitely and
BALB/c skin grafts to survive for 
 
z
 
 50 d without further in-
tervention. The protocol induces long-term allograft sur-
vival, but the mechanism is unknown. We now report: (
 
a
 
)
addition of thymectomy to the protocol permitted skin al-
lografts to survive for 
 
.
 
 100 d, suggesting that graft rejec-
tion in euthymic mice results from thymic export of allore-
active T cells. (
 
b
 
) Clonal deletion is not the mechanism of
underlying long-term graft survival, as recipient thymecto-
mized mice were immunocompetent and harbor alloreactive
T cells. (
 
c
 
) Induction of skin allograft acceptance initially
depended on the presence of IFN-
 
g
 
, CTLA4, and CD4
 
1
 
 T
cells. Addition of anti-CTLA4 or anti–IFN-
 
g
 
 mAb to the
protocol was associated with prompt graft rejection, whereas
anti–IL-4 mAb had no effect. The role of IFN-
 
g
 
 was con-
firmed using knockout mice. (
 
d
 
) Graft survival was associ-
ated with the absence of IFN-
 
g
 
 in the graft. (
 
e
 
) Long-term
graft maintenance required the continued presence of CD4
 
1
 
T cells. The results suggest that, with modification, our
short-term protocol may yield a procedure for the induction
of long-term graft survival without prolonged immunosup-
pression. (
 
J. Clin. Invest.
 
 
 
1998. 101:2446–2455.) Key words:
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• 
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Introduction
 
We have previously reported that treatment of C57BL/6 mice
with a single transfusion of BALB/c donor spleen cells (donor-
specific transfusion, DST)
 
1
 
 and a brief course of anti-CD154
mAb permits BALB/c islet grafts to survive indefinitely (1, 2)
and BALB/c skin grafts to survive for 
 
z
 
 50 d (3). The protocol
is based on the observation that presentation of antigen in the
absence of costimulation leads to T cell nonresponsiveness (4–
10). We hypothesize that when graft recipients are treated with
DST and anti-CD154 mAb: (
 
a
 
) alloantigen is presented by
transfused splenocytes, (
 
b
 
) costimulation is prevented by
blocking CD40–CD154 interaction and subsequent upregula-
tion of B7 (11, 12), and (
 
c
 
) unresponsiveness to the alloanti-
gens present in the transfusion is permissive to continued ac-
ceptance of the tissue allograft. The mechanism by which this
protocol induces long-term allograft survival and the mecha-
nism by which long-term skin allografts are ultimately rejected
are not known.
The experiments reported here were designed to deter-
mine if late rejection of successful allografts in mice treated
with DST and anti-CD154 mAb is mediated by alloreactive
thymic emigrants. We also sought to identify cell types and sol-
uble mediators required for the initial acceptance and subse-
quent maintenance of skin allografts, and to determine if the
protocol leads to a state of microchimerism in recipient mice.
In this report, we define tolerance functionally as a state of
long-term graft acceptance in the absence of immunosuppres-
sion. This functional definition, it should be noted, is different
from the “immunological” definition of tolerance as the ab-
sence of any detectable immune response to a graft in the ab-
sence of immunosuppression.
We hypothesized that treatment with DST and anti-CD154
mAb would impede the priming of alloreactive CD4
 
1
 
 and
CD8
 
1
 
 T cells and skew the balance of Th1- and Th2-type cy-
tokines. This hypothesis was based on studies demonstrating
that treatment of bone marrow allograft recipients with anti-
CD154 mAb (
 
a
 
) blocks acute and chronic graft vs host disease
(13) and (
 
b
 
) decreases both the number of alloreactive CD4
 
1
 
thoracic duct lymphocytes and the expression of IFN-
 
g
 
, IL-2,
and perforin mRNA (14). It was also based on reports that
heart allograft survival in animals treated with anti-CD154
mAb and donor spleen cells is associated with inhibition of in-
tragraft Th1-type cytokines and reciprocal up-regulation of
Th2-type cytokines (15).
We observed that induction of tolerance to skin allografts
with DST and anti-CD154 mAb depends on the presence of
CD4
 
1
 
 T cells, IFN-
 
g
 
, and CTLA4, suggesting, surprisingly,
that allograft tolerance induction may not be an exclusive
function of Th2-type CD4
 
1
 
 T cells. In contrast, long-term graft
maintenance appeared to require the presence of peripheral
CD4
 
1
 
 T cells, and was associated with the absence of IFN-
 
g
 
 in
the graft 7 d after surgery. Finally, we found that eventual re-
jection of skin allografts initially accepted by euthymic mice
results in part from continuing export of alloreactive T cells by
the thymus, suggesting that our protocol had blocked the prim-
ing of peripheral alloreactive T cells. The results identify
mechanisms by which transplantation in the absence of contin-
uous immunosuppression can be achieved.
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Methods
 
Animals.
 
C57BL/6 (H-2
 
b
 
), BALB/c (H-2
 
d
 
), and C3H/HeJ (H-2
 
k
 
)
mice were obtained from the National Cancer Institute (Frederick,
MD). C57BL/6-
 
Prkdc
 
scid
 
/
 
Prkdc
 
scid
 
 mice (H-2
 
b
 
, referred to as C57BL/
6-
 
scid
 
 mice) and C57BL/6 mice in which the IL-4 (16), IL-10 (17), or
IFN-
 
g
 
 (18) genes were disrupted by homologous recombination were
obtained from The Jackson Laboratory (Bar Harbor, ME). Mice
were certified to be specific pathogen-free, housed in microisolator
cages, and given ad libitum access to autoclaved food and water. They
were maintained in accordance with local and federal guidelines (De-
partment of Health, Education, and Welfare Publication National In-
stitutes of Health [NIH] 78-23, 1985).
 
Skin transplantation.
 
Skin graft recipients were male C57BL/6
mice or male C57BL/6-
 
scid
 
/
 
scid
 
 mice 6–8 wk of age. Cells used for
DST and full-thickness skin specimens for transplantation were ob-
tained from female BALB/c mice 4–6 mo of age. Donated skin was
prepared and transplanted as described (3). Skin graft survival was
assessed three times weekly. Time of rejection was defined as the first
day on which the entire epidermal surface of the graft was necrotic.
This typically occurred within a few days after the first sign of rejec-
tion in grafts lost soon after transplantation and within 2 wk in the
case of grafts lost months after transplantation.
 
Treatment of skin allograft recipients with donor-specific transfu-
sion and anti-CD154 mAb.
 
BALB/c mice were killed in 100% CO
 
2
 
.
Spleens were removed, dispersed in sterile medium (RPMI-1640),
washed, and counted. Cell viability was assayed by Trypan blue ex-
clusion, and was 
 
.
 
 90% in all cases. The MR1 hamster anti–mouse
CD154 mAb was produced as ascites in 
 
scid
 
 mice (19, 20). Antibody
concentration in ascites was determined by ELISA. Anti-CD154 as-
cites was administered at doses of 0.25 mg/mouse. Skin allograft re-
cipients received either no treatment, a single transfusion of donor
spleen cells, four doses of anti-CD154 mAb during a 2-wk interval, or
combined therapy with both reagents. Each donor-specific transfu-
sion consisted of 10 
 
3
 
 10
 
6
 
 viable spleen cells in a volume of 0.5 ml
given via the tail vein 7 d before grafting. Four 0.25-mg doses of anti-
CD154 mAb were given intraperitoneally twice weekly beginning on
the day of spleen cell injection (i.e., standard protocol).
 
Thymectomy.
 
In certain experiments, anesthetized C57BL/6
mice 4–6 wk of age were thymectomized as previously described (21).
Completeness of thymectomy was assessed at the conclusion of ex-
periments by visual inspection.
 
T cell subset depletion.
 
In vivo depletion of CD4
 
1
 
 and CD8
 
1
 
 T
cell subsets used mAbs produced by the rat anti–mouse hybridomas
GK1.5 (anti-CD4) and 2.43 (anti-CD8) obtained from the American
Type Culture Collection (Rockville, MD) as described (22). Anti-
body was produced as ascites in 
 
scid
 
 mice and immunoglobulin con-
centration was measured by radial immunodiffusion (The Binding
Site, San Diego, CA). To deplete CD4
 
1
 
 or CD8
 
1
 
 cells, mice were
given 0.5 mg of the appropriate mAb intraperitoneally for three con-
secutive days. This protocol was documented by flow microfluorime-
try to deplete 
 
.
 
 90% of CD4
 
1
 
 and 
 
.
 
 95% of CD8
 
1
 
 T cells 48 h after
the last dose of mAb.
 
Treatment with antibodies against IL-4, IFN-
 
g
 
, and CTLA4.
 
Mono-
clonal rat IgG1 antibodies that react with mouse IL-4 and IFN-
 
g
 
 were
obtained from 11B11 and R4-6A2 hybridomas, respectively (Ameri-
can Type Culture Collection). Antibodies were produced in 
 
scid
 
mice. Antibody concentration was measured as described above.
Mice received 1 mg of the appropriate mAb intraperitoneally every
other day for 14 d beginning 1 wk before grafting (on the same day as
treatment with DST).
Hamster monoclonal antibody directed against CTLA4 (UC10-
4F10-11) was obtained from PharMingen (San Diego, CA). Mice
were given 0.075 mg in a volume of 0.2 ml intraperitoneally on days
 
2
 
7, 
 
2
 
6, and 
 
2
 
5 before the placement of skin grafts on day 0. Control
hamster immunoglobulin was purchased from Sigma Chemical Co.
(St. Louis, MO) and administered at the same dose and concentration
on the same schedule.
 
Mixed lymphocyte reactions (MLRs).
 
Responder cells for cyto-
kine assays were negatively selected from spleen and lymph node
cells by incubation with anti-HSA (J11d), anti-Fc
 
g
 
R (2.462), and anti-
B220 (RA3.6B2) mAb followed by mouse anti–rat kappa- (MAR
18.5) conjugated MACS
 
®
 
 beads (Miltenyi Biotec, Auburn, CA) and
passage over a MIDI MACS column. Cells were 95% CD3
 
1
 
 by flow
cytometry. Culture supernatants were harvested at times indicated
and assayed for the presence of immunoreactive IL-4 and IFN-
 
g
 
.
Stimulator cells were T cell depleted and irradiated as described (1).
 
Measurement of IL-4 and IFN-
 
g
 
 concentration.
 
Antibodies di-
rected against mouse IL-4 (11B11) and mouse IFN-
 
g
 
 (R4-6A2) were
used at concentrations of 1 and 3 
 
m
 
g/ml, respectively. ELISA plates
(Corning Glass, Corning, NY) were coated overnight at 4
 
8
 
C with 50
 
m
 
l/well of antibody diluted in 0.1M Na
 
2
 
HPO
 
4
 
 (pH 9.0) and washed
twice with Dulbecco’s PBS (D-PBS). Nonspecific binding was
blocked using 10% horse serum in D-PBS for 30 min. After four
washes with D-PBS containing 0.05% Tween-20 (D-PBS/Tween),
standards and experimental samples were added to plates (100 
 
m
 
l/
well) for a second overnight incubation at 4
 
8
 
C. Standards were di-
luted in the same culture medium used for the MLRs. Standards
ranged from 7.8 to 2,000 U/ml for IL-4 and 7.8 to 2,000 pg/ml for IFN-
 
g
 
.
Plates were washed six times with D-PBS/Tween and then reacted
with biotinylated secondary antibodies (100 
 
m
 
l) for IL-4 (BVD6-24G,
0.5 
 
m
 
g/ml; PharMingen) and for IFN-
 
g
 
 (XMG1.2, 0.25 
 
m
 
g/ml; Phar-
Mingen). After 1 h of incubation at 25
 
8
 
C, plates were washed eight
times with D-PBS/Tween and reacted with 100 
 
m
 
l of avidin-horse rad-
ish peroxidase conjugate (Vector Laboratories, Burlingame, CA) for
45 min at 25
 
8
 
C. Plates were then washed eight times with D-PBS/
Tween, washed twice with D-PBS, and then reacted with 
 
o
 
-phen-
ylenediamine (100 
 
m
 
l, 1 mg/ml in pH 5.0 0.05M Na
 
2
 
HPO
 
4
 
, 0.025M
Na
 
3
 
C
 
6
 
H
 
5
 
O
 
7
 
). The reaction was stopped after 10–20 min by the addi-
tion of 25 
 
m
 
l of 3 N HCl. Optical density was measured spectrophoto-
metrically at a wavelength of 490 nm.
 
Detection of donor-origin DNA by PCR.
 
The PCR assay for the
presence of donor class I MHC DNA has been described (3). This
nested PCR technique was used to test for donor class I in DNA ob-
tained from spleen, lymph nodes, liver, and lung. This method was
documented to detect 0.01% BALB/c spleen cells in a mixture con-
taining 99.99% C57BL/6 spleen cells.
 
Detection of cytokine mRNA by reverse-transcriptase (RT)-PCR.
 
To detect mRNA encoding IL-4, IFN-
 
g
 
, IL-12R
 
b
 
2, and TCRC
 
b
 
, to-
tal RNA was extracted from skin grafts or normal BALB/c skin using
a modification of a standard guanidinium thiocyanate procedure (23).
Briefly, 20 mM vanadyl ribonucleoside complexes (VRC; GIBCO
BRL, Bethesda, MD) were added to the denaturing solution and the
RNA pellet was dissolved in H
 
2
 
O containing 10 mM EDTA to re-
move trace VRCs, reprecipitated, and dissolved in H
 
2
 
O. RT-PCR
was performed as described (24) using published primer sequences
for rat TCRC
 
b
 
 (24), mouse IL-4, and IFN-
 
g
 
 (25). The primer se-
quences for IL-12R
 
b
 
2 were designed using GCG prime software
(Genetics Computer Group) and the published sequence for IL-
12R
 
b
 
2 (26). The sequences are: forward primer 5
 
9
 
-TCT TCT TCA
CTT CCG CAT AC, and reverse primer 5
 
9
 
-CTC CAA TTA CTC
CAA CTT CC (predicted product size 302 bp). PCR buffer contain-
ing 10 mM Tris-HCl, 50 
 
m
 
M KCl, pH 8.3, and either 1.5 mM MgCL
 
2
 
(TCRC
 
b
 
) or 2.5 mM MgCL
 
2
 
 (IL-4, IFN-
 
g
 
, IL12R
 
b
 
2) and was per-
formed for 30 cycles using threefold dilutions of cDNA. Each cycle
consisted of 94
 
8
 
C, 30 s; 55
 
8
 
C, 30 s; 72
 
8
 
C, 60 s. Positive controls for
each primer were run using either mRNA from C57BL/6 spleen cells
stimulated with concanavalin A (TCRC
 
b
 
, IL-12R
 
b
 
2, IFN-
 
g
 
) or
mRNA from EL-4 cells stimulated with phorbol myristate and iono-
mycin (mouse control RNA; PharMingen).
 
Adoptive transfer protocols.
 
Spleen cells were obtained from do-
nor C57BL/6 mice that had received the pretreatments listed in Table
I. Cells were washed in RPMI-1640, counted, and assessed for viabil-
ity by the method of Trypan blue exclusion. Varying doses of viable
cells in a volume of 0.5 ml were injected into recipients intravenously
via the tail vein. Recipients were C57BL/6-scid mice that had borne
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BALB/c skin grafts for z 10 d before spleen cell transfusion. Grafts
were fully healed at the time of transfusion. Duration of graft survival
was calculated from the day of transfer (day 0).
Statistics. Average duration of graft survival is presented as the
median. Graft survival among groups was compared using the
method of Kaplan and Meier (27); the equality of allograft survival
distributions for animals in different treatment groups was tested us-
ing the log rank statistic (28). P values , 0.05 were considered statis-
tically significant.
Results
Prolonged survival of skin allografts in mice treated with DST, 
anti-CD154 mAb, and thymectomy
We first tested the hypothesis that delayed rejection of skin al-
lografts in euthymic mice treated with DST and anti-CD154
mAb is due to alloreactive T cells that emigrate from the thy-
mus after completion of treatment. C57BL/6 (H-2b) mice were
thymectomized and then given anti-CD154 mAb on days 27,
24, 0, and 14, and BALB/c (H-2d) DST on day 27 relative to
BALB/c skin grafting (day 0) in conformity with our standard
protocol. Nearly all (n 523/24) thymectomized mice treated in
this way retained their grafts for . 100 d (Fig. 1). In contrast,
z 80% of identically treated euthymic mice (with or without
sham thymectomy) rejected grafts within 100 d (P , 0.001), an
observation consistent with previous results (3). The median
survival times (MST) of BALB/c skin allografts on thymecto-
mized C57BL/6 mice given no treatment, DST alone, or anti-
CD154 mAb alone were 8, 7, and 13 d, respectively.
Thymectomized mice given DST, anti-CD154 mAb, and skin 
allografts are immunocompetent and harbor alloreactive T cells
Adoptive transfer of spleen cells from euthymic mice given
DST, anti-CD154 mAb, and skin allografts leads to rejection
of identical allografts present on C57BL/6-scid/scid mice (scid
mice) (3). Based on our first result, we hypothesized that adop-
tive transfer of spleen cells from thymectomized mice given
DST, anti-CD154 mAb, and skin allografts would not lead to
rejection of MHC-identical allografts on scid mice. This hy-
pothesis proved incorrect.
Spleen cells were obtained from thymectomized C57BL/6
mice that had been given DST and anti-CD154 mAb and had
borne BALB/c skin allografts for . 100 d. Adoptive transfer
of these spleen cells to C57BL/6-scid mice bearing BALB/c
(H-2d) or third party C3H/HeJ (H-2k) skin grafts led to rejec-
tion of both types of grafts. Rejection of the C3H/HeJ grafts
occurred promptly after transfer (MST 5 10 d). Rejection of
the BALB/c skin allografts occurred later (MST 5 41 d, P ,
0.001, Table I). Adoptive transfer of spleen cells from control
C57BL/6 mice that had been thymectomized up to 100 d previ-
ously but not otherwise treated led to prompt rejection of both
C3H/HeJ and BALB/c skin allografts present on C57BL/6-scid
mice (MST 5 10 d in both cases, Table I). Consistent with pre-
vious observations (3), spleen cells from euthymic C57BL/6
mice treated with DST, anti-CD154 mAb, and bearing long-
term grafts promptly rejected BALB/c skin grafts in C57BL/6-
scid mice (MST 5 11 d, Table I).
We also tested mixtures of spleen cells from euthymic con-
trol C57BL/6 mice and spleen cells prepared from thymecto-
mized C57BL/6 mice that had been given DST and anti-CD154
mAb and had borne BALB/c skin allografts for . 100 d. Adop-
tive transfer of these spleen cell mixtures led to prompt rejec-
tion of BALB/c skin grafts present on C57BL/6-scid mice
(MST 5 8 d, Table I).
Treatment with anti-CD4 but not anti-CD8 mAb for 3 d leads 
to rejection of successful skin allografts in thymectomized mice 
Table I. Survival of Skin Allografts on scid Mice after Adoptive Transfer of Spleen Cells
Treatment of C57BL/6 spleen cell donors
Median survival
time of BALB/c
skin grafts on
C57BL/6-scid mice
after cell transfer
Survival of individual BALB/c and C3H/HeJ 
grafts (d) after transfer for each cell dose
Cell
number BALB/c grafts
C3H/HeJ
grafts
d
Thymectomy; DST 1 anti-CD154 mAb; BALB/c skin graft for . 100 d 41* 15 3 106 41, 43 ND
20 3 106 41, 43, 49 ND
25 3 106 38, 42, 52 10, 10
75 3 106 39, 40, 41 ND
No treatment; no thymectomy; no graft 9‡ 15 3 106 7, 10 ND
20 3 106 8, 8, 8 ND
25 3 106 8, 8, 9, 9, 11, 13, 14, 8, 13
75 3 106 10 ND
No thymectomy; DST 1 anti-CD154 mAb; BALB/c skin graft . 100 d 11‡ 25 3 106 8, 8, 10, 11, 13, 18, 18 6, 13
Thymectomy; no other treatment 10‡ 25 3 106 9, 10, 10, 12 8, 9, 12, 13
No treatment; no thymectomy; no graft 8‡ 20 3 106 6, 8, 8 ND
Thymectomy, DST, anti-CD154 mAb, BALB/c 1
 skin graft for . 100 d 20 3 106
Spleen cells from four groups of C57BL/6 mice were transfused at the doses indicated into C57BL/6-scid/scid mice bearing a completely healed
BALB/c or C3H/HeJ skin graft. All donor mice that had long-term BALB/c skin allografts in place had been treated with anti-CD154 mAb on days
27, 24, 0, and 13, and BALB/c DST on day 27 relative to skin grafting on day 0 in conformity with our standard protocol. *‡P , 0.001. Within each
group of cell donors, there were no statistically significant effects of cell dose. ND, not done; no graft, no primary sensitization.
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that had received DST and anti-CD154 mAb either 2 wk or 3 
mo earlier
Because thymectomized mice given DST, anti-CD154 mAb,
and skin allografts were found to be immunocompetent and to
harbor alloreactive T cells, we hypothesized that graft survival
was dependent on an active mechanism rather than permanent
deletion of all alloreactive cells. We tested this hypothesis in
thymectomized C57BL/6 mice given DST, anti-CD154 mAb,
and a BALB/c skin graft (Table II). Recipient mice were then
given depleting doses of either anti-CD4 or anti-CD8 mAb
Table II. Survival of BALB/c Skin Allografts on C57BL/6 Mice
Recipient treatments
Experiment Thymectomy DST 1 a-CD154
mAb treatment schedule
relative to grafting Skin allograft survival MST
d d
1 2 1 2 16, 18, 29, 32, 46, 63, 66, 66, 68 46*
2 1 a-CD4 (211 to 29) 11, 11, 12, 13, 18, 18, 21, 21, 21, 22 18‡
2 2 a-CD4 (211 to 29) 11, 12, 12, 12, 15, 15, 18, 18, 18 15§
2 2 1 2 17, 17, 24, 52, 52, 63, 66, 87, 101, 117 58i
2 1 a-CD8 (211 to 29) 17, 17, 17, 28, 34, 38, 38, 40 31¶
2 2 a-CD8 (211 to 29) 10, 10, 10, 10, 10 10**
3 1 1 2 63, 74, . 102, . 102, 108, . 168 . 100‡‡
1 1 a-CD4 (211 to 29) 12, 12, 14, 17, 17, 19, 31, 34, 34, 40 18§§
1 1 a-CD8 (211 to 29) 17, 28, 33, 38, 47, 63, 66, 77, 90, 122 55ii
1 1 a-CD4 (114 to 116) 17, 19, 21, 24, 26, 28, 31, 31, 45 26¶¶
1 1 a-CD8 (114 to 116) 17, 124, 133, 142, 147, . 168, 184, . 200 . 138***
4 1 1 a-CD4 (1107 to 1109) 123, 133, 133, 135 133‡‡‡
1 1 a-CD8 (1107 to 1109) . 290, . 290, . 290 . 290§§§
Four groups of C57BL/6 mice were given BALB/c skin allografts on day 0. Some of the allograft recipients in each group were also given anti-CD154
mAb on days 27, 24, 0, and 13, and BALB/c DST on day 27 relative to skin grafting in conformity with our standard protocol. Some mice in each
category were also treated with a depleting mAb directed against either CD4 or CD8 on the days indicated. All times are relative to placement of the
skin graft on day 0. Statistical comparisons: * vs ‡, P , 0.005; i vs ¶, P , 0.025; § vs **, P , 0.001; ‡‡ vs §§ and ¶¶, P , 0.001; §§ vs ii, P , 0.01; ‡‡ vs ii, P ,
0.05; ¶¶ vs ***, P , 0.001; ‡‡ vs ***, P 5 NS; ‡‡‡ vs §§§, P , 0.025.
Figure 1. Survival of skin al-
lografts. Groups of 4–6-wk-old 
C57BL/6 mice were randomized to 
undergo thymectomy, sham-thy-
mectomy, or no surgery. After re-
covery, thymectomized animals 
were further randomized and given 
either no treatment, DST alone, 
anti-CD154 mAb alone, or the com-
bination of DST and mAb. Sham-
thymectomized and nonoperated 
animals were given DST plus anti-
CD154 mAb. All animals also re-
ceived a BALB/c skin allograft. 
DST (10 3 106 BALB/c spleen cells) 
was given on day 27 relative to 
transplantation, and anti-CD154 
mAb was given as four doses of 0.25 
mg each on days 27, 24, 0, and 14. 
Results are shown as the Kaplan-
Meier probability of survival. Cen-
sored data (animals still alive with 
successful grafts at the termination 
of the study) are indicated by verti-
cal bars. The probability of graft 
survival in the group treated with 
thymectomy, DST, and mAb is sta-
tistically greater than that in any 
other group (P , 0.001).
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daily on days 14–16 (experiment 3) or 107–109 (experiment 4)
after grafting. At both time points, anti-CD4 mAb treatment
was associated with prompt rejection of the graft, whereas
anti-CD8 mAb treatment had no effect on graft survival (Ta-
ble II, experiments 3 and 4). In the case of the mice treated
with mAb on days 14–16 after transplantation, the MST of
grafts after giving the first dose of antibody was 12 d in the
anti-CD4 group but . 126 d in the anti-CD8 group (P , 0.001,
Table II, experiment 3). In the case of mice treated with mAb
on days 107–109 after successful grafting, MST after the first
dose of antibody was 26 d in the anti-CD4 group and . 183 d
in the anti-CD8 group (P , 0.025, Table II, experiment 4).
Pretreatment with either anti-CD4 or anti-CD8 mAb shortens 
allograft survival in C57BL/6 mice subsequently given DST, 
anti-CD154 mAb, and BALB/c skin allografts
These data suggested that maintenance of permanent skin al-
lografts on thymectomized mice after treatment with DST and
anti-CD154 mAb is an active process that depends on CD41 T
cell populations. We therefore hypothesized that the presence
of CD41 cells would be required at the time DST and anti-
CD154 mAb were being administered.
We first tested this hypothesis in thymectomized C57BL/6
mice given either anti-CD4 or anti-CD8 mAb daily on days 11,
10, and 9 before grafting (Table II). The recipients then re-
ceived anti-CD154 mAb on days 27, 24, 0, and 14, and
BALB/c DST on day 27 relative to BALB/c skin grafting on
day 0 in conformity with our standard protocol. Pretreatment
with anti-CD4 mAb reduced allograft survival from a median
of . 100 d in controls to only 18 d (P , 0.001, Table II, experi-
ment 3). Pretreatment with anti-CD8 mAb also reduced al-
lograft survival, but to a lesser extent (55 d, P , 0.05, Table II,
experiment 3).
Experiments were also performed in euthymic recipients
using the same treatment protocols. Pretreatment with anti-
CD4 mAb reduced allograft survival from a median of 46 d in
controls to 18 d (P , 0.005, Table II, experiment 1). Pretreat-
ment with anti-CD8 mAb also reduced allograft survival from
a median of 58 d in controls to 31 d (P , 0.025, Table II, exper-
iment 2).
We also tested the effect of administration of anti-CD4 and
anti-CD8 mAbs on allograft survival in euthymic animals that
received no DST or anti-CD154 mAb before grafting. Consis-
tent with previous reports (29), graft survival in mice treated
with anti-CD4 mAb was statistically superior to that observed
in mice treated with anti-CD8 mAb (P , 0.001, Table II). How-
ever, in the absence of DST and anti-CD154 mAb, neither
anti-CD4 nor anti-CD8 mAb treatment was associated with
clinically significant prolongation of graft survival (MST 5 15
and 10 d, Table II, experiments 1 and 2, respectively).
BALB/c skin allograft survival is reduced in thymectomized 
C57BL/6 mice given anti-CTLA4 mAb in addition to DST and 
anti-CD154 mAb
These data suggested that both initial acceptance and mainte-
nance of skin allografts in mice treated with DST and anti-
CD154 mAb involve an active T cell–dependent process. Be-
cause this process appeared to involve the down-regulation of
alloreactivity, we hypothesized that signaling via the B7-
CTLA4 receptor pathway might be required.
To test this hypothesis, thymectomized C57BL/6 mice were
randomized into two groups. The first group received anti-
CTLA4 mAb daily on days 7, 6, and 5 before grafting; the sec-
ond group received control hamster Ig on the same schedule.
Both groups of recipients also received anti-CD154 mAb on
days 27, 24, 0, and 14, and BALB/c DST on day 27 relative
to BALB/c skin grafting on day 0. All recipients treated with
anti-CTLA4 mAb rapidly rejected their skin grafts (MST 5 8 d,
Table III). In contrast, graft survival in recipients of hamster Ig
was . 22 d (P , 0.01, Table III).
IFN-g but not IL-4 or IL-10 is required for the initial 
acceptance of skin allografts by mice treated with DST and 
anti-CD154 mAb
Studies in knockout mice. We hypothesized that the active
process involved in the acceptance and maintenance of skin al-
lografts in mice treated with DST and anti-CD154 mAb de-
pends on cytokines that modulate T cell function. We studied the
possible role of Th1- and Th2-type cytokines using C57BL/6
mice in which the IFN-g, IL-4, or IL-10 gene had been dis-
rupted by homologous recombination (knockout mice). Eu-
thymic knockout recipient mice were given BALB/c DST,
anti-CD154 mAb, and BALB/c skin allografts in conformity
with our standard protocol. We observed comparable survival
of BALB/c skin allografts in normal, IL-4 knockout, and IL-10
knockout C57BL/6 mice (MST 5 51, 22, and 39 d, respectively,
Table IV, P 5 NS). In contrast, median survival of allografts in
IFN-g knockout mice was reduced to 15 d (P , 0.001 vs all
other groups).
In vivo neutralization of IFN-g and IL-4. We also studied
the possible role of Th1- and Th2-type cytokines in the accep-
tance of skin allografts using neutralizing mAbs directed
against IFN-g and IL-4. Thymectomized C57BL/6 mice were
randomized to three groups. Two groups were given neutraliz-
ing doses of either anti–IFN-g or anti-IL-4 mAb on days 27,
25, 23, 21, 11, 13, and 15 relative to grafting on day 0. All
recipients in each group were treated with anti-CD154 mAb
on days 27, 24, 0, and 14, and with BALB/c DST on day 27
relative to BALB/c skin grafting in conformity with our stan-
dard protocol. Consistent with the observations made in
knockout mice, skin allograft survival in recipients treated
with anti–IFN-g mAb (MST 5 15 d) was shorter than that in
controls (. 72 d P , 0.01) or in recipients treated with anti–
IL-4 mAb (. 72 d, P , 0.01, Table IV).
Reduced production of IFN-g by spleen cells from mice given 
anti-CD154 mAb and skin allografts with or without DST
Because IFN-g but not IL-4 appeared to be important in the
initial acceptance of skin allografts by mice given DST and
Table III. Skin Allograft Survival in Mice Treated with Donor 
Specific Transfusion and Anti-CD154 mAb with and without 
Intercurrent Anti-CTLA4 mAb
Donor treatment n MST Survival of individual grafts
d
Anti-CTLA4 5 8* 7, 8, 8, 8, 8
Hamster IgG 6 . 22‡ 8, . 22, . 22, . 22, . 22, . 22,
C57BL/6 mice were given anti-CD154 mAb on days 27, 24, 0, and 14,
and BALB/c DST on day 27 relative to BALB/c skin grafting on day 0
in conformity with our standard protocol. Treated mice were random-
ized into two groups, one of which was given hamster IgG on days 27,
26, and 25 relative to grafting, and the other anti-CTLA4 mAb on the
same schedule. * vs ‡, P , 0.01.
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anti-CD154 mAb, we assayed for their production by spleen
and lymph node cells in MLRs. In these experiments, re-
sponder cells were obtained from mice 7 d after skin grafting.
As expected, production of IFN-g by cells from euthymic
C57BL/6 mice given only BALB/c skin allografts was high
(. 2,000 pg/ml) in the presence of BALB/c stimulator cells. In
contrast, its production by cells from mice given DST plus anti-
CD154 mAb in addition to the skin allograft was low to unde-
tectable (, 18 pg/ml).
Similarly, production of IFN-g by cells from thymecto-
mized C57BL/6 mice given only BALB/c skin allografts was
also high, and its production by cells from thymectomized mice
given DST plus anti-CD154 mAb in addition to the allograft
was low to undetectable. This result was obtained when either
BALB/c or third party (C3H/HeJ) cells were used as stimula-
tors. Interestingly, production of IFN-g by cells from thymec-
tomized, allografted mice given anti-CD154 mAb alone was
also low to undetectable in the presence of either BALB/c or
C3H/HeJ stimulator cells.
Production of IL-4 by cells obtained from each group of
thymectomized mice was low under all experimental condi-
tions. The highest value was 180 U/ml but most values were
less than background (, 61 U/ml). Production of both IFN-g
and IL-4 by cells from thymectomized mice that received no
treatment and no graft was minimal to undetectable.
Detection of cytokines in skin allografts by PCR
Skin specimens from normal, untreated BALB/c mice and
from euthymic C57BL/6 mice bearing BALB/c allografts were
assayed for the presence of T cell receptor Cb (TCRCb), IL-12
receptor b2 (IL-12Rb2), IL-4, and IFN-g mRNA by RT-PCR
assay. Allograft skin specimens were obtained 7 d after graft-
ing onto mice that had received either DST plus anti-CD154
mAb or no treatment. TCRCb and IL-12Rb2 mRNA, but nei-
ther IL-4 nor IFN-g mRNA could be detected in normal
BALB/c skin (data not shown). In contrast, high levels of IFN-g,
TCRCb, and IL-12Rb2 mRNAs but no IL-4 mRNA could be
detected in skin allograft specimens from both untreated and
DST plus anti-CD154 mAb treated euthymic recipients (data
not shown).
It was possible that the IFN-g mRNA observed in the al-
lografts obtained from DST plus anti-CD154 mAb-treated eu-
thymic recipients was present in T cells that had recently emi-
grated from the thymus. To exclude this possibility, we tested
skin allografts obtained from three groups of thymectomized
recipients 7 d after graft placement. The first group of C57BL/6
recipients received DST and anti-CD154 mAb in conformity
with our standard protocol; the second group received the
anti-CD154 mAb component alone; the third group was un-
treated.
In contrast to the results obtained using euthymic recipient
mice, little to no IFN-g mRNA was detectable in grafted skin
from thymectomized recipients that had been given both anti-
CD154 mAb and DST (n 5 6, Fig. 2). IFN-g mRNA was, how-
ever, detected in grafted skin from both the untreated group
(n 5 6) and the anti-CD154 mAb-only (n 5 3) groups. TCRCb
and IL-12Rb2 mRNAs but no IL-4 mRNA could be detected
in skin allograft specimens from any group.
No evidence of lymphohemopoietic chimerism in 
thymectomized C57BL/6 mice given BALB/c DST,
anti-CD154 mAb, and BALB/c skin allografts
It has been hypothesized that the maintenance of allograft sur-
vival requires, or is facilitated by, the presence of donor-origin
lymphohemopoietic cells in graft recipients (30). We used a
PCR assay to determine if lymphohemopoietic chimerism
were present in C57BL/6 mice that had been given BALB/c
DST, anti-CD154 mAb, and BALB/c skin allografts. The PCR
assay detects donor MHC (H2-Kd) class I DNA and has been
documented to be capable of detecting BALB/c DNA in 1:104
mixtures of BALB/c and C57BL/6 spleen cells (3). No BALB/c
DNA was detected in spleen, lymph nodes (axillary, brachial,
and inguinal), liver, or lung taken from any of six thymecto-
mized C57BL/6 mice treated with BALB/c DST and anti-
CD154 mAb, and that had borne BALB/c skin allografts for
. 100 d (data not shown).
Discussion
We report five principal findings. (a) Thymectomy prevents
late rejection of successful skin allografts in mice treated with
DST and anti-CD154 mAb. (b) The induction of tolerance to
skin allografts by treatment with DST and anti-CD154 mAb
depends on the presence of IFN-g, CTLA4, and CD41 and (to
Table IV. Survival of Skin Allografts on Mice Deficient in IFN-g, IL-4, or IL-10
Recipients mAb n MST Survival of individual grafts
d
Euthymic C57BL/6 — 15 51* 11, 18, 21, 25, 39, 43, 43, 51, 53, 56, . 82, . 82, . 82, . 100, . 100
Euthymic C57BL/6-IL-4 knockout — 14 22* 11, 13, 13, 13, 18, 20, 21, 23, 74, . 82, . 82, . 100, . 100, . 100
Euthymic C57BL/6-IFN-g knockout — 9 15‡ 13, 13, 13, 13, 15, 18, 20, 20, 28
Euthymic C57BL/6-IL-10 knockout — 10 39* 11, 11, 13, 13, 37, 40, 47, 47, 70, 75
Thymectomized C57BL/6 — 5 . 72§ 56, . 59, . 72, . 72, . 72
Thymectomized C57BL/6 Anti–IL-4 5 . 72§ . 72, . 72, . 72 . 72, . 72
Thymectomized C57BL/6 Anti–IFN-g 5 15i 13, 13, 15, 22, . 72
Recipient mice were given anti-CD154 mAb on days 27, 24, 0, and 14, and BALB/c DST on day 27 relative to BALB/c skin grafting on day 0 in
conformity with our standard protocol. Comparisons of graft survival on normal and congenic cytokine knockout C57BL/6 mice were performed us-
ing euthymic recipients. Comparisons of graft survival in the presence or absence of anticytokine neutralizing antibodies were performed in thymec-
tomized animals. The 11B11 anti–IL-4 and R4-6A2 anti–IFN-g mAbs were given intraperitoneally at a dose of 1 mg on days 27, 25, 23, 21, 1, 3, and
5 relative to grafting. Statistical comparisons: * vs ‡, P , 0.001; § vs i, P , 0.01.
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a lesser extent) CD81 T cells. (c) Long-term maintenance of
skin allografts requires the presence of CD41 T cells. (d)
Treatment of thymectomized skin allograft recipients with
both DST and anti-CD154 mAb (but not with mAb alone) is
associated with absence of IFN-g in the graft 7 d after surgery.
(e) Finally, the protocol appears not to lead to a state of micro-
chimerism.
We hypothesize that long-term allograft survival in proto-
col-treated mice involves DST-induced activation of allore-
sponsive T cells, possibly leading to deletion and/or anergy of
Th1 alloreactive cells. Our data also suggest that induction
of graft survival involves CD41 T cell activation, the presence
of IFN-g, and functional availability of CTLA4 receptors. A
role for CD41 regulatory cells in allograft responsiveness has
been suggested in other experimental models (29, 31–33). Our
data do not identify the source of the IFN-g required for initial
graft acceptance. IFN-g is, however, known to be produced by
Th1-type CD41 T cells, CD81 T cells, and natural killer (NK)
cells (34). The critical role for CD41 cells in the initial accep-
tance of skin allografts suggests that Th1-type CD41 cells or
CD41 NK T cells could have a regulatory function in the in-
duction of allotolerance. The presence of IFN-g suggests that
the induction of allotolerance by DST and anti-CD154 mAb, is
not simply a function of the regulation of Th1-type effector
T cell activity by Th2-type cytokines. The absence of IL-4 in
grafts destined for long-term survival, our observation of long-
term graft survival in IL-4 knockout mice, and previous re-
ports of enhance graft survival in IL-4 knockout mice (35, 36)
are consistent with this view.
Our data also demonstrate that anti-CTLA4 mAb inter-
feres with the induction of graft survival. Interaction of B7
with CTLA4 is hypothesized to lead to down-regulation of
activated T cells (37), and it may be speculated that graft sur-
vival induced by DST and anti-CD154 mAb requires ligation
of CTLA4 receptor on alloreactive effector T cells. Alterna-
tively, CTLA4 ligation may be required to generate regulatory
cells. CTLA4 engagement is reportedly required for the induc-
tion of unresponsiveness (38).
Our data generated using anti-CTLA4 mAb contrast with
the recent report that combination treatment with anti-CD154
mAb and CTLA4-Ig prolongs heart and skin allograft survival
(39). CTLA4-Ig is known, however, to block not only the
CTLA4 receptor, but also B7-CD28 mediated costimulation
(40, 41). CTLA4-Ig blockade of CD28 may circumvent the re-
quirement for CTLA4-dependent down-regulatory activity in
the early stages of graft survival documented in the present
study. Because the earlier report using combined treatment
with anti-CD154 mAb and CTLA4-Ig monitored the survival
of skin allografts for only 50 d, it cannot be determined if its
tolerizing effect is as durable as that achieved with DST and
anti-CD154 mAb.
We have previously shown that treatment of euthymic
C57BL/6 mice with a single transfusion of BALB/c donor
spleen cells and a brief course of anti-CD154 mAb extends
BALB/c skin graft survival to a median of z 50 d (3). Approx-
imately 20% of the allografts in that study were observed to
survive for . 100 d, a level of durability that was remarkable
given that all tolerance induction procedures were completed
within 5 d of transplantation and that no form of chronic im-
munosuppression was administered.
The late failure of skin allografts in euthymic recipients
treated with DST and anti-CD154 mAb in the earlier studies
could have been due, in part to, the emergence of new allore-
active thymic emigrants after the conclusion of the treatment.
The present thymectomy data support this view, although they
do not formally exclude the possibility that the thymus plays
some other, as yet unknown, role in the maintenance of pe-
ripheral T cell alloreactivity. The addition of thymectomy to
our basic short-term protocol enabled us to achieve nearly
100% survival of skin allografts for . 100 d. Several grafts sur-
vived for . 330 d. We conclude that the combination of DST
and anti-CD154 mAb induces peripheral but not central al-
lograft tolerance.
We can also conclude that the long-term survival of al-
lografts observed in thymectomized recipients treated with
DST and anti-CD154 mAb is not due to microchimerism (30,
42–47). Our PCR data suggest that few (, 0.01%) if any
lymphohemopoietic cells of BALB/c origin were present in
thymectomized C57BL/6 animals given DST and anti-CD154
mAb, and bearing long-term BALB/c skin grafts.
The extension of skin allograft survival by thymectomy
could be interpreted to suggest that all peripheral alloreactive
T cells undergo deletion or anergy during treatment with DST
and anti-CD154 mAb. If this interpretation were correct,
adoptively transferred spleen cells from treated animals would
not lead to rejection of MHC-identical allografts on scid mice.
This proved not to be the case. Spleen cells obtained from
Figure 2. Expression of cytokine mRNA in skin grafts. Cytokine 
mRNA expression in BALB/c skin allografts removed from thymec-
tomized C57BL/6 mice 7 d after graft placement. Recipient mice had 
received in addition to the graft either no treatment (left), anti-
CD154 mAb alone (center), or both DST and anti-CD154 mAb 
(right). After reverse transcription, 4 ml of cDNA product were seri-
ally diluted threefold, and amplified. Aliquots of 20 ml of PCR prod-
ucts were electrophoresed on 1.5% agarose gels and then stained with 
ethidium bromide. All PCR products are of the expected size. Each 
column shows results for each dilution from a single representative 
skin graft from the indicated group. A total of six grafts in the no 
treatment group, six from the DST plus anti-CD154 mAb group, and 
three from the anti-CD154 mAb alone group were analyzed for each 
cytokine, and in all cases comparable results were obtained.
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thymectomized C57BL/6 mice that had been given DST and
anti-CD154 mAb and had borne BALB/c skin allografts for
. 100 d were found to be capable of rejecting BALB/c skin
grafts on C57BL/6-scid recipients. It does remain possible,
however, that the process of adoptive transfer could nonspecif-
ically reverse the anergic state.
The suggestion that residual alloreactive cells were present
in tolerant mice was further supported by challenge graft ex-
periments. Challenge of thymectomized, graft-bearing recipi-
ents led to rejection of both BALB/c and third party challenge
grafts (Markees, T.G., unpublished observations). The results
of the adoptive transfer and challenge graft experiments sug-
gest that that peripheral tolerance induction by DST and anti-
CD154 mAb represents a state of split tolerance (48) that de-
pends on additional processes for its maintenance.
This additional process does not appear to be infectious
tolerance, as it cannot be transferred to adoptive recipients
(31). Our observation of long-term skin allograft survival in
thymectomized recipients also contrasts with recent observa-
tions made in a swine model of transplantation (49). In that
model, allotolerance to kidneys was induced by a short course
of cyclosporin A, but only in euthymic recipients. It was postu-
lated that thymic emigrants with regulatory ability prevented
rejection (49). In this model, however, donors and recipients
were matched for MHC class II and mismatched only for
MHC class I and minor antigens. Our data indicate that CD41
regulatory cells are required for maintenance of graft survival,
and we suggest that this regulatory function in recipients mis-
matched at both class I and class II can be overwhelmed by the
activity of alloreactive thymic emigrants.
We hypothesize that the maintenance of allografts in ani-
mals treated with DST and anti-CD154 mAb is due to a defi-
ciency of intragraft Th1-type cytokines. Our study of skin
grafts in thymectomized animals treated with DST and anti-
CD154 mAb demonstrated the total, or near total, absence of
IFN-g message by postoperative day 7. In contrast, IFN-g
mRNA was detected in grafts placed on mice treated with
anti-CD154 mAb alone; our data show that such grafts are des-
tined for rapid rejection. The possibility that the absence of
IFN-g is due to immune deviation is, however, weakened by
our observation of IL-12Rb2 mRNA in grafts destined for
long-term survival. IL-12Rb2 expression stops when CD41 T
cells commit to the Th2-type pathway, and the expression of
IL-12Rb2 mRNA has been associated with the absence of IL-4
production (50). The absence of IFN-g suggests, however, that
the cells expressing IL-12Rb2 mRNA are anergic.
Parenthetically, it is of interest to note that the Th1-type
cytokine IFN-g appears to play a dual role in allotolerance in-
duction by DST and anti-CD154 mAb. IFN-g is required for
the induction of tolerance, but it is absent in grafts that are
destined for long-term survival. These observations are consis-
tent with reports that IFN-g can both suppress and activate T
cells (51, 52). This could represent an example of the compart-
mentalization of the immune response as a function of expres-
sion of IFN-g in the graft (activation) vs regional lymph nodes
(suppression).
Our data show that (a) thymectomy is associated with very
long-term skin graft survival in animals treated with DST and
anti-CD154 mAb, and (b) that CD41 but not CD81 T cells are
required for long-term maintenance of skin allografts. The im-
portance of CD41 T cells is consistent with previous studies
(29, 31–33). These observations suggest that the fate of long-
term skin allografts is a function of the relative balance be-
tween tolerized CD41 cells with regulatory activity and allo-
reactive T cells in peripheral tissues. This interpretation is
supported by our observation of a high frequency of late (. 50 d)
skin allograft rejection in euthymic mice treated with DST and
anti-CD154 mAb. We favor the hypothesis of Sprent et al. (48)
that, during the induction of tolerance, high affinity alloreac-
tive T cells are deleted or anergized. As a corollary, it could be
speculated that residual low affinity alloreactive T cells are po-
larized towards a Th2-type cell, and that graft failure is ulti-
mately due to the release of new populations of high affinity
alloreactive T cells. If this last speculation is correct, it would
imply that not only thymectomy, but any procedure capable of
deleting or anergizing such cells would prolong graft survival.
It can be argued that anti-CD154 mAb is an immunosup-
pressive agent. Anti-CD154 mAb can prolong the survival of
mouse pancreatic islet allografts (1). In the present study, how-
ever, treatment of thymectomized mice with anti-CD154 mAb
alone proved incapable of prolonging allograft survival as
would be expected of a conventional immunosuppressive
pharmaceutical.
Induction of unresponsiveness to skin allografts is a note-
worthy achievement (53, 54), given the presence of large num-
bers of Langerhans cells in this tissue (55). Until recently, pro-
longed skin graft survival has typically required extraordinary
interventions such as the use of neonatal recipients (56), radia-
tion (57, 58), or other forms of generalized immunosuppres-
sion (31, 59, 60). We have now achieved long-term (. 100 d)
survival of nearly all fully allogeneic skin grafts that are placed
on adult thymectomized mice treated with a donor-specific
transfusion and a short-term course of anti-CD154 mAb. The
result suggests that modifications of our short-term tolerance-
induction protocol, originally developed for the transplanta-
tion of pancreatic islets (1), may yield a clinically applicable
procedure for the induction of durable allotolerance without
prolonged immunosuppression.
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